ABSTRACT
Silperisone is a tolperisone like organosilicon compound with centrally acting muscle relaxant properties. Studies in mice showed that silperisone may have less propensity to cause CNS depressant or motor side effects than tolperisone or other antispastic drugs. In cats and rats, silperisone was an effective suppressant of monosynaptic and polysynaptic spinal reflexes and decerebrate rigidity. Its suppressant effect on the spinal reflexes was also demonstrated in the isolated hemisected rat spinal cord in vitro. The in vivo potency and efficacy of silperisone by i.v administration were similar to those of tolperisone and eperisone. However, in cats by intraduodenal administration and in mice by oral administration its duration of action was much longer and its functional bioavailability much higher than of the other two drugs. With regard to its profile of actions silperisone was similar to tolperisone with minor differences. The most striking difference was in pontine facilitation and bulbar inhibition of the patellar reflex. Tolperisone depressed both, whereas silperisone inhibited only the former. The mechanism underlying the spinal reflex depressant effects of silperisone involves the blockade of voltage gated neuronal sodium and calcium channels leading to a decreased release of excitatory transmitter and reduced neuronal excitability. In addition, silperisone has potassium channel blocking effect, which is stronger than that of tolperisone. Silperisone is absorbed rapidly and is extensively metabolized in rats. However, its metabolism in dogs and particularly in humans is much less extensive. The elimination half‐life of silperisone in humans is 12 to 16 h, so that it can be administered once or twice daily. Phase I clinical studies with silperisone at doses up to 150 mg/day failed to detect any adverse effects at plasma concentrations considered to be effective in the preclinical tests. These findings suggested that silperisone might be a useful antispastic drug. However, findings in chronic animal toxicity studies led to the discontinuation of silperisone's development.
(1)
[ Chemical structure of silperisone. ]
Keywords: Antispasmodics, Decerebrate rigidity, Muscle relaxants, Organosilicon drugs, Silperisone, Sodium channel blockers, Spasticity, Spinal reflex, Tolperi‐sone, Tremor
Full Text
The Full Text of this article is available as a PDF (184.2 KB).
REFERENCES
- 1. Bains W, Tacke R. Silicon chemistry as a novel source of chemical diversity in drug design. Curr Opin Drug Disc Devel 2003; 6:526–543. [PubMed] [Google Scholar]
- 2. Bielik N, Farkas S, Kocsis P. Studies on the mechanism of action of RGH‐5002, a centrally acting muscle relaxant, using whole cell patch clamp technique. Neurobiology 1997; 5:43–45. [PubMed] [Google Scholar]
- 3. Düring, T , Koppenhöfer E. Effects of silperisone on the excitation process in Ranvier nodes. Gen Physiol Biophys 2001; 20:157–173. [PubMed] [Google Scholar]
- 4. Farkas S, Berzsenyi P, Kárpáti E, Kocsis P, Tarnawa I. Simple pharmacological test battery to assess efficacy and side effect profile of centrally acting muscle relaxant drugs. J Pharmacol Toxicol Meth 2005; 52:264–273. [DOI] [PubMed] [Google Scholar]
- 5. Farkas S, Földeák S, Kárpáti E, et al Organosilane derivatives, pharmaceutical compositions containing them and process for preparing same. European Patent 1992; EP 0468825 (US 5198446; 1993).
- 6. Farkas S, Kárpáti E. Electromyographic measurement of the flexor reflex in cats for testing centrally acting muscle relaxants. Pharmacol Res Comm 1988; 20(Suppl I):141–142. [Google Scholar]
- 7. Farkas S, Kárpáti E. The pharmacology of RGH‐5002, a new centrally acting muscle relaxant with a long duration of action and less motor side‐effects. Pharmacol Res 1992; 25(Suppl 2):25–26. [Google Scholar]
- 8. Farkas S, Ono H. Participation of NMDA and non‐NMDA excitatory amino acid receptors in the mediation of spinal reflex potentials in rats: An in vivo study. Br J Pharmacol 1995; 114:1193–1205. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Farkas S, Tarnawa I, Berzsenyi P. Effects of some centrally acting muscle relaxants on spinal root potentials: A comparative study. Neuropharmacology 1989; 28:161–173. [DOI] [PubMed] [Google Scholar]
- 10. Fehér M, Juvancz P, Szontágh M. Effect of Mydocalm in the rehabilitation of hemiparesis. Balneol Rehabilit Gydgyfürdõügy 1985; 6:201–205. [Google Scholar]
- 11. Gémesi L, Kapás M. High‐performance liquid chromatographic method for the determination of RGH‐5002 in human, rabbit and rat plasma. J Pharm Biomed Anal 1996; 14:1233–1239. [DOI] [PubMed] [Google Scholar]
- 12. Hinck D, Koppenhöfer E. Tolperisone — A novel modulator of ionic currents in myelinated axons. Gen Physiol Biophys 2001; 20:413–429. [PubMed] [Google Scholar]
- 13. Ito T, Hori M, Furukawa K. Pharmacological studies of 1‐(2, 3‐dimethyl‐4‐methoxyphenyl)‐2‐methyl‐3‐(1‐pyrrolidinyl)‐1‐propanone hydrochloride (AD‐2239), a centrally acting muscle relaxant. Arch Int Pharmacodyn Ther 1985; 275:105–122. [PubMed] [Google Scholar]
- 14. Kocsis P, Farkas S, Fodor L, et al Tolperisone‐type drugs inhibit spinal reflexes via blockade of voltage‐gated sodium and calcium channels. J Pharmacol Exp Ther 2005; 315:1237–1246. [DOI] [PubMed] [Google Scholar]
- 15. Kuroiawa Y, Sobue I, Tazaki Y, Nakanishi T, Ohtomo E, Itahara K. Effects of E‐0646 on cases of spasticity: A double‐blind comparison using tolperisone hydrochloride. Clin Eval 1981; 9:391–491. [Google Scholar]
- 16. Matsunaga M, Uemura Y, Yonemoto Y, et al Long‐lasting muscle relaxant activity of eperisone hydrochloride after percutaneous administration in rats. Jpn J Pharmacol 1997; 73:215–220. [DOI] [PubMed] [Google Scholar]
- 17. Miskolczi P, Vereczkey L, Frenkl R. Gas‐liquid chromatographic method for the determination of tolperisone in human plasma: pharmacokinetic and bioavailability studies. J Pharm Biomed Anal 1987; 5:695–700. [DOI] [PubMed] [Google Scholar]
- 18. Morikawa K, Oshita M, Yamazaki M. Pharmacological studies of the new centrally acting muscle relaxant 4′‐ethyl‐2‐methyl‐3‐pyrrolidinopropiophenone hydrochloride. Arzneimitteforschung 1987; 37:331–336. [PubMed] [Google Scholar]
- 19. Nance PW, Sheremata WA, Lynch SG, et al Relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosis. Arch Neurol 1997; 54:731–736. [DOI] [PubMed] [Google Scholar]
- 20. Newman PM, Nogues M, Newman PK, Weightman D, Hudson P. Tizanidine in the treatment of spasticity. Eur J Clin Pharmacol 1982; 23:31–35. [DOI] [PubMed] [Google Scholar]
- 21. Ochiai T. and Ishida R. Pharmacological studies on 6‐amino‐2‐fluoromethyl‐3‐(o‐tolyl)‐4(3H)‐quinazoli‐none (afloqualone), a new centrally acting muscle relaxant (I). Jpn J Pharmacol 1981; 31:491–501. [DOI] [PubMed] [Google Scholar]
- 22. Ono H, Fukuda H, Kudo Y. Mechanisms of depressant action of muscle relaxants on spinal reflexes: Participation of membrane stabilizing action. J Pharmacobiodyn 1984; 7:171–176. [DOI] [PubMed] [Google Scholar]
- 23. Pórszász J, Nádor K, Gibiszer‐Pórszász K, Barankay T. Pharmacologic einer neuen interneuron‐lahmenden Substanz l‐piperidino‐2‐methyl‐3‐(p‐tolyl)‐propan‐3‐on. Arzneimitteforschung 1961; 11:257–260. [Google Scholar]
- 24. Pratzel HG, Aiken RG, Ramm S. Efficacy and tolerance of repeated oral doses of tolperisone hydrochloride in the treatment of painful muscle spasm: Results of a prospective placebo‐controlled double‐blind trial. Pain 1996; 67:417–425. [DOI] [PubMed] [Google Scholar]
- 25. Sakitama K, Ozawa Y, Aoto N, Nakamura K, Ishikawa M. Pharmacological properties of NK‐433, a new centrally acting muscle relaxant. Eur J Pharmacol 1995; 273:47–56. [DOI] [PubMed] [Google Scholar]
- 26. Tacke R, Zilch H. Sila‐substitution — a useful strategy for drug design Endeavour 1986; 10:191–197. [DOI] [PubMed] [Google Scholar]
- 27. Tanaka K, Kaneko T, Yamatsu K. Effects of 4′‐ethyl‐2‐methyl‐3‐piperidinopropiophenone on experimental contracture and spinal cord activities. Folia Pharmacol Japon 1981; 77:511–520. [PubMed] [Google Scholar]
- 28. Terjéki E, Pátfalusi M, Trafikánt G Kapás M. Distribution and elimination of RGH‐5002 in rats. Acta Physiol Hung 1995; 83:143–150. [PubMed] [Google Scholar]